MLYS Insider Trading Activity and SEC Form 4 Filings
MLYS insider trading summary
Over the past 12 months, insiders at Mineralys Therapeutics, Inc. (MLYS) reported 79 sales worth $130.7M by 8 insiders and 10 open-market purchases worth $43.8M by 5 insiders on SEC Form 4. Net insider selling was $86.9M.
Latest MLYS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Jon Congleton | Chief Executive Officer | Sell | $1.9M (75,000 @ $25.46) |
| Sep 22, 2026 | Brian Taylor Slingsby | Director | Sell | $3.0M (104,320 @ $28.81) |
| Sep 21, 2026 | Eric Warren | Chief Commercial Officer | Sell | $209K (7,438 @ $28.12) |
| Sep 15, 2026 | Daphne Karydas | Director | Sell | $86K (3,000 @ $28.58) |
| Aug 21, 2026 | Eric Warren | Chief Commercial Officer | Sell | $193K (7,437 @ $25.98) |
| Aug 10, 2026 | David Malcom Rodman | Chief Medical Officer | Sell | $59K (2,170 @ $27.09) |
| Jul 21, 2026 | Eric Warren | Chief Commercial Officer | Sell | $200K (7,438 @ $26.87) |
| Jul 17, 2026 | David Malcom Rodman | Chief Medical Officer | Sell | $11K (416 @ $26.53) |
| Jul 15, 2026 | David Malcom Rodman | Chief Medical Officer | Sell | $169K (6,349 @ $26.61) |
| Jul 13, 2026 | Jon Congleton | Chief Executive Officer | Sell | $291K (10,700 @ $27.24) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.